Accessibility Statement

2021 Year in Review

2021 YIR DAR Headshot

To Our Lilly Shareholders,

Two years into the COVID-19 pandemic, our company continues to deliver on our commitment to patients, thanks to the passion and tenacity of our Lilly team. Our global colleagues came to our labs and factories, connected with customers, and kept our sites running throughout the pandemic. Others innovated and collaborated from home to deliver results. We achieved things we never thought possible, from developing and manufacturing COVID-19 antibodies in record time, to submitting a new drug application entirely as a remote team.

As a result, over 47 million people across the globe benefitted from our medicines last year. We are grateful for the dedication of our team and our partnerships with health care providers, which enable our work to reach so many.

The global COVID-19 pandemic underscored that Lilly’s purpose – uniting caring with discovery to create medicines that make life better for people around the world – is clearer and more relevant than ever.

Importantly, our capacity and capability to fulfill this purpose is also stronger than ever. We’ve driven solid results over the last several years, successfully launched new medicines, and invested in high-impact R&D that has set us up for a truly exciting new era of patient care.

Our Work is Not Done

While Lilly’s accomplishments in 2021 are important, it’s where we are going that most excites us. Bringing new medicines to patients is our priority, and we have a remarkable opportunity ahead of us to make life better for millions more people around the world facing difficult-to-address health challenges such as cancer, obesity and Alzheimer’s disease.

In 2022, we anticipate several potential new medicine and new indication launches, regulatory submissions, key data disclosures and Phase 3 trial initiations.

With the depth of our pipeline, we’re in a stronger place than ever before, and see enormous opportunities ahead to address some of the world’s worst health conditions.

Thank you for your confidence in Lilly – I’m proud of where we’ve taken the company amidst the many challenges around us and energized by where we’re headed. We are honored by your support and commitment.

2021 YIR DAR Signature

David A. Ricks

Chair and CEO

Lilly Cautionary Statement Regarding Forward-Looking Statements

The statements made in the 2021 Year in Review contain forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. Words such as “estimate”, “project”, “intend”, “expect”, “believe”, “target”, “anticipate” and similar expressions are intended to identify forward-looking statements. The company’s sustainability targets, goals, and commitments, as well as its operations, results, business, goals, and strategy may be affected by factors including, but not limited to, the impact of the evolving COVID-19 pandemic (or any other public health threat) and the global response thereto; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; competitive developments affecting current products and the company’s pipeline; regulatory actions regarding currently marketed products; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured; the impact and outcome of business development transactions and related integration costs; the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war or other costs or uncertainties related to doing business in foreign jurisdictions; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions or shortages, including as a result of demand, labor shortages, third-party performance or regulatory actions relating to our facilities; and changes or developments in laws and regulations, including health care reform.  

For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.

Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations at